JAMA's policy does not go far enough

BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7536.305-a (Published 02 February 2006) Cite this as: BMJ 2006;332:305
  1. Stephen J Senn, professor of statistics (stephen@stats.gla.ac.uk)
  1. Department of Statistics, University of Glasgow, Glasgow G12 8QQ

    EDITOR—The main objection I have to the JAMA policy is not that it requires independent validation of analysis but that it seems to require it only for studies sponsored by the pharmaceutical industry.1 There have been a whole host of examples, ranging from McBride's “studies” …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription